Bausch + Lomb to launch Phase 3 trial of dry‑eye drop after Phase 2 miss
read at Endpoints ↗Negative readoutNeutral
Bausch + Lomb announced plans to move its dual‑action dry‑eye drop into a Phase 3 study.
The decision follows a Phase 2 trial that did not meet its primary endpoint.
CEO Brent Saunders said the results were better than expected and justify further development.
The company will design the next study to address the shortcomings and aims to demonstrate efficacy.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal”
read at Endpoints ↗93 words · retrieved Aug 24
comments(0)
5-min edit window · permanent after that